Skip to main content

Table 4 Tumor response at 12 months after the combination therapy

From: Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor

Response

Patients, No. (%)

P value

CRAFITY-low (n = 21) *

CRAFITY-intermediate (n = 18) *

CRAFITY-high (n = 3) *

CR

6 (28.57%)

8 (44.44%)

0 (0.00%)

-

PR

10 (47.62%)

6 (33.33%)

2 (66.67%)

-

SD

4 (19.05%)

3 (16.67%)

1 (33.33%)

-

PD

1 (4.76%)

1 (5.56%)

0 (0.00%)

-

ORR

16 (76.19%)

14 (77.77%)

2 (66.67%)

0.916

DCR

20 (95.24%)

17 (94.44%)

3 (100.00%)

0.005

  1. * Data are presented as n (%). CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us